No abstract

DERIVO 2 Embolization Device (DED2) is a new addition to the market and promises better radiopacity. 1 Aim of study The purpose of this study was to evaluate the safety and efficacy of the DED2. Methods We conducted a retrospective multicenter analysis at six interventional facilities. Patients with unruptured or ruptured intracranial aneurysms were included. The primary objective was angiographic aneurysm occlusion at 6 months as measured by the OKM grading scale. Clinical outcome according to mRS was evaluated at 6 months, with major morbidity defined as mRS 3-5. Results We included 37 patients treated with the DED2 between August 2020 and July 2021. Five patients had ruptured aneurysms. 27 patients were female, 10 male, with a medium age of 60. The median mRS was 0 (range 0-4). Average aneurysm size was 9.1 (7.9) mm, while average neck size was 6.8 (6.3) mm. In all cases the DED2 opened upon deployment. Thirty patients were eligible for clinical follow-up (81.1%). 25 (83.3%) had an mRS of 0 or 1, with no clinical deterioration in patients with pre-existing significant morbidity. Three patients died during the follow-up period, two of whom had ruptured aneurysms initially. Follow-up imaging was available in 27 patients (90%), with 23 (85.2%) demonstrating satisfactory aneurysm occlusion OKM grade C-D. Conclusion The DED2 is both safe and effective in the treatment of ruptured and unruptured intracranial aneurysms.